CHOA PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,613 KRW | -0.12% |
|
-0.62% | -18.58% |
| 2023 | ChoA Pharmaceutical Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2022 | ChoA Pharmaceutical Co., LTD.(KOSDAQ:A034940) dropped from S&P Global BMI Index | CI |
| Sales 2022 | 68.88B 49.73M 3.98B | Sales 2023 | 62.97B 45.47M 3.64B | Capitalization | 61.37B 44.31M 3.55B |
|---|---|---|---|---|---|
| Net income 2022 | 561M 405K 32.46M | Net income 2023 | -10.51B -7.59M -608M | EV / Sales 2022 | 1.21 x |
| Net Debt 2022 | 10.23B 7.39M 592M | Net Debt 2023 | 13.14B 9.49M 760M | EV / Sales 2023 | 1.18 x |
| P/E ratio 2022 |
130
x | P/E ratio 2023 |
-5.84
x | Employees | 258 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.12% | ||
| 1 week | -0.62% | ||
| Current month | -11.18% | ||
| 1 month | -11.18% | ||
| 3 months | -11.32% | ||
| 6 months | -24.27% | ||
| Current year | -18.58% |
1 week
1 594.00
1 638.00
1 month
1 570.001 864.00
Current year
1 570.002 015.00
1 year
1 570.002 410.00
3 years
1 570.005 420.00
5 years
1 570.006 670.00
10 years
1 570.008 930.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sung-Bae Cho
CEO | Chief Executive Officer | 51 | 16/10/14 |
Sung-Hwan Cho
CEO | Chief Executive Officer | 53 | 17/02/02 |
Joon-Hyeong Son
BRD | Director/Board Member | 56 | 31/03/04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Won-Ki Cho
CHM | Chairman | 84 | 31/12/87 |
Sung-Hwan Cho
CEO | Chief Executive Officer | 53 | 17/02/02 |
Joon-Hyeong Son
BRD | Director/Board Member | 56 | 31/03/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 1,613 | -0.12% | 32,654 |
| 29/04/24 | 1,615 | +0.62% | 43,002 |
| 26/04/24 | 1,605 | -0.74% | 27,749 |
| 25/04/24 | 1,617 | -0.49% | 59,942 |
| 24/04/24 | 1,625 | +0.49% | 39,875 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
CHOA PHARMACEUTICAL CO,.LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products are mainly for treatment of indigestion, gastric ulcer, duodenal ulcer, gastritis, gastric hyperacidity, intestinal disorder, constipation, diarrhea, stomachache, calcium deficiency, fatigue, iron deficiency anemia, neurasthenia, hypertension, hyperlipidemia, circulatory disorder, medicine poisoning, hepatic disease, allergic rhinitis, cough, cold, rheumatoid arthritis and others. It also provides nutrition products, health drinks, mixed drinks, beverages for children, cosmetics and others.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.58% | 36.11M | |
| +19.27% | 43.18B | |
| +24.05% | 23.23B | |
| +15.11% | 14.6B | |
| +12.33% | 13.54B | |
| +38.36% | 11.5B | |
| -7.63% | 6.79B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.31B |
- Stock Market
- Equities
- A034940 Stock
